GSK Acquired New Hepatic Program From Wave Life Sciences
The $12 million deal expands GSK's liver-focused siRNA portfolio using Wave's proprietary RNA design platform.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe collaborative pharmaceutical partnerships ultimately benefit patients through lower drug prices?
GSK has paid an upfront fee of $12 million to acquire a hepatic program from Wave Life Sciences, building on a collaboration agreement originally signed in 2022. The new asset focuses on liver health through small interfering RNA technology and was selected under the existing eight-program option deal.
Why it matters
The acquisition reflects GSK's strategy to bolster its hepatology pipeline as it moves toward clinical development. By integrating this specific program, the company adds to its liver-focused portfolio, which already includes the phase 2 candidate gatuzosiran.
The candidate utilizes Wave Life Sciences' PRISM platform and SpiNA design to develop small interfering RNA therapies. This asset is one of four programs GSK has selected for development out of the eight options established in their 2022 agreement.
The players
GSK
A global biopharmaceutical company focusing on vaccines, specialty medicines, and general medicines across respiratory, HIV, and oncology therapeutic areas.
Wave Life Sciences
A clinical-stage biotechnology company developing genetic medicines using its proprietary PRISM platform for RNA editing and oligonucleotide design.
The details
The program employs small interfering RNA (siRNA) — synthetic molecules that inhibit the expression of specific disease-causing genes by degrading messenger RNA. Wave's PRISM platform allows for the precise chemical modification of these RNA strands, while its SpiNA (Short interfering RNA) design improves the stability and delivery of the molecules to the liver. By targeting gene pathways directly at the cellular level, the technology aims to reduce the production of proteins associated with liver dysfunction.
Timeline
2022: GSK and Wave Life Sciences signed the initial collaboration agreement.
January 2026: GSK had selected four programs for advancement.
February 2026: GSK returned rights for a lead RNA editing candidate.
September 30, 2026: GSK announced the acquisition of the new hepatic program.
The Tech Race
This acquisition follows the trajectory established by the 2022 hepatic siRNA collaboration, signaling GSK's continued prioritization of liver disease research. The move advances the existing partnership framework as GSK shifts focus toward maturing its select portfolio of gene-silencing assets.
The clinical progression of this program depends on future milestone successes, with three additional programs from the original deal still awaiting selection. Patients and the scientific community should monitor upcoming disclosures regarding the specific liver diseases this candidate aims to treat.
The takeaway
GSK's investment confirms its commitment to RNA-based liver therapies as a core pillar of its specialty medicines business. Observers should track the progression of the remaining three programs within the Wave collaboration to gauge the long-term success of the PRISM platform in the clinic.
Further reading
For broader trends in genetic medicine and liver therapeutics, explore our Biotech section.
Live Poll
Do you believe collaborative pharmaceutical partnerships ultimately benefit patients through lower drug prices?
